Friday, September 30, 2011

AstraZeneca settles with Handa to delay Seroquel XR generic entry upto 2016- But Threat still persists as litigation with other companies is still ongoing

AZN today announced that it has settled Seroquel XR litigation with Handa, delaying generic launch upto 2016. Handa being first to file, other generic players will have to wait till Handa launches. However if ongoing litigation with other players leads to invalidation of XR patent, than the generic players can enter earlier. Indian based generic company - Intas subsidiary Accord has also challenged Seroquel XR patents and the court is expected to rule this year on it. Accord has received tentative FDA approval. Other player litigating the XR patent are Sandoz, Torrent, Anchen, Osmotica, TEva, Intellipharmaceuticals.